Clinical Trial Update: Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated valacyclovir to prevent cytomegalovirus infection in patients undergoing donor stem cell transplantation. The study status is complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytomegalovirus Infection

Drugs mentioned

• Valacyclovir (Valacyclovir)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Cancer | Phase 3 | Status: COMPLETED